Testing the vaccine potential of PilV, PilX and ComP, minor subunits of Neisseria meningitidis type IV pili

Vaccine

Volumn 29, Issue 40, 2011, Pages 6858-6865

  Cehovin, Ana ^a   Kroll, J Simon ^a   Pelicic, Vladimir ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Neisseria meningitidis; Type IV pili; Vaccine

Indexed keywords

BACTERIAL VACCINE; COMP ANTIBODY; PILIN; PILV ANTIBODY; PILX ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BLOOD SAMPLING; CELL ADHESION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOGENICITY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NEISSERIA MENINGITIDIS TYPE IV PILI; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANTIGENIC VARIATION; BACTERIAL PROTEINS; BACTERIAL VACCINES; BLOOD BACTERICIDAL ACTIVITY; CELL ADHESION; CELL AGGREGATION; CELL MOVEMENT; CHILD, PRESCHOOL; CONSERVED SEQUENCE; DNA TRANSFORMATION COMPETENCE; FEMALE; FIMBRIAE, BACTERIAL; HUMANS; IMMUNE SERA; MALE; MENINGOCOCCAL INFECTIONS; NEISSERIA MENINGITIDIS;

EID: 80052329240     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.060     Document Type: Article

References (61)

1. WHO Epidemics of meningococcal disease, African meningitis belt, 2001. Wkly Epidemiol Rec 2001, 76:281-288.
2. Campbell H., Borrow R., Salisbury D., Miller E. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine 2009, 27(Suppl. 2):B20-B29.
3. Snape M.D., Pollard A.J. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis 2005, 5(1):21-30.
4. Stephens D.S., Greenwood B., Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007, 369(9580):2196-2210.
5. Girard M.P., Preziosi M.P., Aguado M.T., Kieny M.P. A review of vaccine research and development: meningococcal disease. Vaccine 2006, 24(22):4692-4700.
6. Jacobsson S., Hedberg S.T., Molling P., Unemo M., Comanducci M., Rappuoli R., et al. Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. Vaccine 2009, 27(10):1579-1584.
7. Pillai S., Howell A., Alexander K., Bentley B.E., Jiang H.Q., Ambrose K., et al. Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B. Vaccine 2005, 23(17-18):2206-2209.
8. Pelicic V. Type IV pili: e pluribus unum?. Mol Microbiol 2008, 68(4):827-837.
9. Maier B., Potter L., So M., Long C.D., Seifert H.S., Sheetz M.P. Single pilus motor forces exceed 100pN. Proc Natl Acad Sci U S A 2002, 99(25):16012-16017.
10. Merz A.J., So M., Sheetz M.P. Pilus retraction powers bacterial twitching motility. Nature 2000, 407(6800):98-102.
11. Lammel C.J., Sweet R.L., Rice P.A., Knapp J.S., Schoolnik G.K., Heilbron D.C., et al. Antibody-antigen specificity in the immune response to infection with Neisseria gonorrhoeae. J Infect Dis 1985, 152(5):990-1001.
12. Poolman J.T., Hopman C.T., Zanen H.C. Immunogenicity of meningococcal antigens as detected in patient sera. Infect Immun 1983, 40(1):398-406.
13. Siegel M., Olsen D., Critchlow C., Buchanan T.M. Gonococcal pili: safety and immunogenicity in humans and antibody function in vitro. J Infect Dis 1982, 145(3):300-310.
14. Tramont E.C. Gonococcal vaccines. Clin Microbiol Rev 1989, 2(Suppl.):S74-S77.
15. Tramont E.C., Boslego J.W. Pilus vaccines. Vaccine 1985, 3(1):3-10.
16. Tramont E.C., Sadoff J.C., Boslego J.W., Ciak J., McChesney D., Brinton C.C., et al. Gonococcal pilus vaccine. Studies of antigenicity and inhibition of attachment. J Clin Invest 1981, 68(4):881-888.
17. Nagy B., Moon H.W., Isaacson R.E., To C.C., Brinton C.C. Immunization of suckling pigs against enteric enterotoxigenic Escherichia coli infection by vaccinating dams with purified pili. Infect Immun 1978, 21(1):269-274.
18. Brinton C.C., Carter M.J., Derber D.B., Kar S., Kramarik J.A., To A.C., et al. Design and development of pilus vaccines for Haemophilus influenzae diseases. Pediatr Infect Dis J 1989, 8(1 Suppl.):S54-S61.
19. Novotny L.A., Adams L.D., Kang D.R., Wiet G.J., Cai X., Sethi S., et al. Epitope mapping immunodominant regions of the PilA protein of nontypeable Haemophilus influenzae (NTHI) to facilitate the design of two novel chimeric vaccine candidates. Vaccine 2009, 28(1):279-289.
20. Kirn T.J., Lafferty M.J., Sandoe C.M., Taylor R.K. Delineation of pilin domains required for bacterial association into microcolonies and intestinal colonization by Vibrio cholerae. Mol Microbiol 2000, 35(4):896-910.
21. Sun D.X., Mekalanos J.J., Taylor R.K. Antibodies directed against the toxin-coregulated pilus isolated from Vibrio cholerae provide protection in the infant mouse experimental cholera model. J Infect Dis 1990, 161(6):1231-1236.
22. Lepper A.W., Elleman T.C., Hoyne P.A., Lehrbach P.R., Atwell J.L., Schwartzkoff C.L., et al. A Moraxella bovis pili vaccine produced by recombinant DNA technology for the prevention of infectious bovine keratoconjunctivitis. Vet Microbiol 1993, 36(1-2):175-183.
23. Criss A.K., Kline K.A., Seifert H.S. The frequency and rate of pilin antigenic variation in Neisseria gonorrhoeae. Mol Microbiol 2005, 58(2):510-519.
24. Seifert H.S., Wright C.J., Jerse A.E., Cohen M.S., Cannon J.G. Multiple gonococcal pilin antigenic variants are produced during experimental human infections. J Clin Invest 1994, 93(6):2744-2749.
25. Virji M., Everson J.S., Lambden P.R. Effect of anti-pilus antisera on virulence of variants of Neisseria gonorrhoeae for cultured epithelial cells. J Gen Microbiol 1982, 128(5):1095-1100.
26. Boslego J.W., Tramont E.C., Chung R.C., McChesney D.G., Ciak J., Sadoff J.C., et al. Efficacy trial of a parenteral gonococcal pilus vaccine in men. Vaccine 1991, 9(3):154-162.
27. Brown D.R., Helaine S., Carbonnelle E., Pelicic V. Systematic functional analysis reveals that a set of seven genes is involved in fine-tuning of the multiple functions mediated by type IV pili in Neisseria meningitidis. Infect Immun 2010, 78(7):3053-3063.
28. Helaine S., Carbonnelle E., Prouvensier L., Beretti J.L., Nassif X., Pelicic V. PilX, a pilus-associated protein essential for bacterial aggregation, is a key to pilus-facilitated attachment of Neisseria meningitidis to human cells. Mol Microbiol 2005, 55(1):65-77.
29. Craig L., Li J. Type IV pili: paradoxes in form and function. Curr Opin Struct Biol 2008, 18(2):267-277.
30. Helaine S., Dyer D.H., Nassif X., Pelicic V., Forest K.T. 3D structure/function analysis of PilX reveals how minor pilins can modulate the virulence properties of type IV pili. Proc Natl Acad Sci U S A 2007, 104(40):15888-15893.
31. Aas F.E., Wolfgang M., Frye S., Dunham S., Lovold C., Koomey M. Competence for natural transformation in Neisseria gonorrhoeae: components of DNA binding and uptake linked to type IV pilus expression. Mol Microbiol 2002, 46(3):749-760.
32. Wolfgang M., van Putten J.P., Hayes S.F., Koomey M. The comP locus of Neisseria gonorrhoeae encodes a type IV prepilin that is dispensable for pilus biogenesis but essential for natural transformation. Mol Microbiol 1999, 31(5):1345-1357.
33. Cehovin A., Winterbotham M., Lucidarme J., Borrow R., Tang C.M., Exley R.M., et al. Sequence conservation of pilus subunits in Neisseria meningitidis. Vaccine 2010, 28(30):4817-4826.
34. Stephens D.S., Whitney A.M., Schoolnik G.K., Zollinger W.D. Common epitopes of pilin of Neisseria meningitidis. J Infect Dis 1988, 158(2):332-342.
35. Rusniok C., Vallenet D., Floquet S., Ewles H., Mouze-Soulama C., Brown D., et al. NeMeSys: a biological resource for narrowing the gap between sequence and function in the human pathogen Neisseria meningitidis. Genome Biol 2009, 10(10):R110.
36. Rothbard J.B., Fernandez R., Wang L., Teng N.N., Schoolnik G.K. Antibodies to peptides corresponding to a conserved sequence of gonococcal pilins block bacterial adhesion. Proc Natl Acad Sci U S A 1985, 82(3):915-919.
37. Virji M., Heckels J.E. Role of anti-pilus antibodies in host defense against gonococcal infection studied with monoclonal anti-pilus antibodies. Infect Immun 1985, 49(3):621-628.
38. Pujol C., Eugène E., de Saint Martin L., Nassif X. Interaction of Neisseria meningitidis with a polarized monolayer of epithelial cells. Infect Immun 1997, 65(11):4836-4842.
39. Forest K.T., Bernstein S.L., Getzoff E.D., So M., Tribbick G., Geysen H.M., et al. Assembly and antigenicity of the Neisseria gonorrhoeae pilus mapped with antibodies. Infect Immun 1996, 64(2):644-652.
40. Chen I., Dubnau D. DNA uptake during bacterial transformation. Nat Rev Microbiol 2004, 2(3):241-249.
41. Wolfgang M., Lauer P., Park H.S., Brossay L., Hebert J., Koomey M. PilT mutations lead to simultaneous defects in competence for natural transformation and twitching motility in piliated Neisseria gonorrhoeae. Mol Microbiol 1998, 29(1):321-330.
42. Merz A.J., So M. Interactions of pathogenic Neisseriae with epithelial cell membranes. Annu Rev Cell Dev Biol 2000, 16:423-457.
43. Tramont E.C. Specificity of inhibition of epithelial cell adhesion of Neisseria gonorrhoeae. Infect Immun 1976, 14(2):593-595.
44. Carbonnelle E., Helaine S., Prouvensier L., Nassif X., Pelicic V. Type IV pilus biogenesis in Neisseria meningitidis: PilW is involved in a step occurring after pilus assembly, essential for fibre stability and function. Mol Microbiol 2005, 55(1):54-64.
45. Borrow R., Balmer P., Miller E. Meningococcal surrogates of protection - serum bactericidal antibody activity. Vaccine 2005, 23(17-18):2222-2227.
46. Fernandes P.J., Guo Q., Waag D.M., Donnenberg M.S. The type IV pilin of Burkholderia mallei is highly immunogenic but fails to protect against lethal aerosol challenge in a murine model. Infect Immun 2007, 75(6):3027-3032.
47. Helm R.A., Seifert H.S. Frequency and rate of pilin antigenic variation of Neisseria meningitidis. J Bacteriol 2010, 192(14):3822-3823.
48. Koomey M. Prepilin-like molecules in type 4 pilus biogenesis: minor subunits, chaperones or mediators of organelle translocation?. Trends Microbiol 1995, 3(11):409-410.
49. Darton T., Guiver M., Naylor S., Jack D.L., Kaczmarski E.B., Borrow R., et al. Severity of meningococcal disease associated with genomic bacterial load. Clin Infect Dis 2009, 48(5):587-594.
50. Fazio C., Neri A., Tonino S., Carannante A., Caporali M.G., Salmaso S., et al. Characterisation of Neisseria meningitidis C strains causing two clusters in the north of Italy in 2007 and 2008. Euro Surveill 2009, 14.(16).
51. Trotter C.L., Chandra M., Cano R., Larrauri A., Ramsay M.E., Brehony C., et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 2007, 31(1):27-36.
52. Trotter C.L., Fox A.J., Ramsay M.E., Sadler F., Gray S.J., Mallard R., et al. Fatal outcome from meningococcal disease - an association with meningococcal phenotype but not with reduced susceptibility to benzylpenicillin. J Med Microbiol 2002, 51(10):855-860.
53. von Gottberg A., du Plessis M., Cohen C., Prentice E., Schrag S., de Gouveia L., et al. Emergence of endemic serogroup W135 meningococcal disease associated with a high mortality rate in South Africa. Clin Infect Dis 2008, 46(3):377-386.
54. Zarantonelli M.L., Lancellotti M., Deghmane A.E., Giorgini D., Hong E., Ruckly C., et al. Hyperinvasive genotypes of Neisseria meningitidis in France. Clin Microbiol Infect 2008, 14(5):467-472.
55. Rudel T., Scheurerpflug I., Meyer T.F. Neisseria PilC protein identified as type-4 pilus tip-located adhesin. Nature 1995, 373(6512):357-359.
56. Buchanan T.M., Pearce W.A., Schoolnik G.K., Arko R.J. Protection against infection with Neisseria gonorrhoeae by immunization with outer membrane protein complex and purified pili. J Infect Dis 1977, 136(Suppl.):S132-S137.
57. Granoff D.M. Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease. Vaccine 2009, 27(Suppl. 2):B117-B125.
58. Welsch J.A., Granoff D. Immunity to Neisseria meningitidis group B in adults despite lack of serum bactericidal antibody. Clin Vaccine Immunol 2007, 14(12):1596-1602.
59. Geoffroy M.C., Floquet S., Metais A., Nassif X., Pelicic V. Large-scale analysis of the meningococcus genome by gene disruption: resistance to complement-mediated lysis. Genome Res 2003, 13(3):391-398.
60. Coureuil M., Lecuyer H., Scott M.G., Boularan C., Enslen H., Soyer M., et al. Meningococcus hijacks a beta2-adrenoceptor/beta-Arrestin pathway to cross brain microvasculature endothelium. Cell 2010, 143(7):1149-1160.
61. Delgado M., Yero D., Niebla O., Gonzalez S., Climent Y., Perez Y., et al. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate. Vaccine 2007, 25(50):8420-8431.